Pfizer reported better-than-expected second-quarter results on Tuesday, powered by strong demand for blood thinner Eliquis and recently acquired drugs, and announced plans for an additional $2.5 billion in savings from cost cutting.
The New York-based drugmaker now expects $9.7 billion in total net savings from its cost slashing through 2029 as it seeks to offset declining COVID-related revenue and restore sustainable growth.